250 related articles for article (PubMed ID: 22272100)
1. Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors.
Lu S; Liu HC; Chen YD; Yuan HL; Sun SL; Gao YP; Yang P; Zhang L; Lu T
Int J Mol Sci; 2011; 12(12):8713-39. PubMed ID: 22272100
[TBL] [Abstract][Full Text] [Related]
2. Ligand-based pharmacophore modeling, atom-based 3D-QSAR and molecular docking studies on substituted thiazoles and thiophenes as polo-like kinase 1 (Plk1) inhibitors.
Chekkara R; Gorla VR; Susithra E; Tenkayala SR
Comb Chem High Throughput Screen; 2014; 17(10):848-58. PubMed ID: 25346190
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model.
Oh Y; Jung H; Kim H; Baek J; Jun J; Cho H; Im D; Hah JM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917995
[TBL] [Abstract][Full Text] [Related]
4. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
5. QSAR-guided pharmacophoric modeling reveals important structural requirements for Polo kinase 1 (Plk1) inhibitors.
Shahin R; Al-Hashimi NN; Daoud NE; Aljamal S; Shaheen O
J Mol Graph Model; 2021 Dec; 109():108022. PubMed ID: 34562852
[TBL] [Abstract][Full Text] [Related]
6. QSAR studies on imidazopyrazine derivatives as Aurora A kinase inhibitors.
Leng Y; Lu T; Yuan HL; Liu HC; Lu S; Zhang WW; Jiang YL; Chen YD
SAR QSAR Environ Res; 2012 Oct; 23(7-8):705-30. PubMed ID: 22971111
[TBL] [Abstract][Full Text] [Related]
7. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking.
Sun G; Fan T; Zhang N; Ren T; Zhao L; Zhong R
Molecules; 2016 Jun; 21(7):. PubMed ID: 27347909
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
Zeng H; Zhang H; Jang F; Zhao L; Zhang J
Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
Shafique S; Bibi N; Rashid S
J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
[TBL] [Abstract][Full Text] [Related]
11.
Shirvani P; Fassihi A
J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
Zhou Y; Yan F; Huo X; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214
[TBL] [Abstract][Full Text] [Related]
14. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
Pan Y; Wang Y; Bryant SH
J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
[TBL] [Abstract][Full Text] [Related]
16. Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2011; 12(3):1605-24. PubMed ID: 21673910
[TBL] [Abstract][Full Text] [Related]
17. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase.
Zhang B; Li Y; Zhang H; Ai C
Int J Mol Sci; 2010 Nov; 11(11):4326-47. PubMed ID: 21151441
[TBL] [Abstract][Full Text] [Related]
19. Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.
Liu HC; Tang SZ; Lu S; Ran T; Wang J; Zhang YM; Xu AY; Lu T; Chen YD
Int J Mol Sci; 2015 Oct; 16(10):24451-74. PubMed ID: 26501259
[TBL] [Abstract][Full Text] [Related]
20. Structure based 3D-QSAR studies of Interleukin-2 inhibitors: Comparing the quality and predictivity of 3D-QSAR models obtained from different alignment methods and charge calculations.
Halim SA; Zaheer-ul-Haq
Chem Biol Interact; 2015 Aug; 238():9-24. PubMed ID: 26051521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
